The content on this site is intended for healthcare professionals only
Dr Fredrik Schjesvold speaks to ecancer about the refractoriness and re-treatment go myeloma in the era of lenalidomide and mABs in the frontline setting.
Dr Schjesvold explains the background go his presentation at MyKe Myeloma 2021. He explains that many people have refractory disease in myeloma and there are three regimens approved for elderly and young people. He then mentions that patients can also be daratumuab refractory in the second line setting.
Dr Schjesvold concludes by discussing what treatment to give to people who are refractory and mentions several drugs that can be used for this purpose.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Choosing 1st line TKI Wisely in patients with CML
